Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Urogen Pharma Ltd
(NQ:
URGN
)
14.74
-0.22 (-1.44%)
Streaming Delayed Price
Updated: 9:46 AM EDT, Mar 28, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
17,457
Open
14.92
Bid (Size)
14.63 (6)
Ask (Size)
14.86 (4)
Prev. Close
14.96
Today's Range
14.56 - 15.25
52wk Range
7.790 - 24.13
Shares Outstanding
30,282,880
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day Session
March 25, 2024
Shares of Landos Biopharma, Inc. (NASDAQ: LABP) rose sharply during Monday’s session following acquisition news.
Via
Benzinga
URGN Stock Earnings: UroGen Pharma Misses EPS, Beats Revenue for Q4 2023
March 14, 2024
URGN stock results show that UroGen Pharma missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023.
Via
InvestorPlace
Performance
YTD
-3.06%
-3.06%
1 Month
-17.90%
-17.90%
3 Month
+2.40%
+2.40%
6 Month
-2.29%
-2.29%
1 Year
+84.08%
+84.08%
More News
Read More
UroGen Pharma Delivers Double Digit JELMYTO® Growth and Prepares for the Next Phase of the Company with on Track Rolling Submission of UGN-102
March 14, 2024
From
UroGen Pharma Ltd.
Via
Business Wire
Earnings Outlook For UroGen Pharma
March 13, 2024
Via
Benzinga
Recap: UroGen Pharma Q3 Earnings
November 14, 2023
Via
Benzinga
Preview: UroGen Pharma's Earnings
November 13, 2023
Via
Benzinga
Earnings Scheduled For March 14, 2024
March 14, 2024
Via
Benzinga
The Latest Analyst Ratings for UroGen Pharma
October 04, 2023
Via
Benzinga
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 08, 2024
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Pharma to Report Fourth Quarter and Full-Year 2023 Financial Results on Thursday, March 14, 2024
March 04, 2024
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Pharma to Present at TD Cowen 44th Annual Health Care Conference
February 26, 2024
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Pharma to Participate at Upcoming Investor Conferences
February 01, 2024
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Initiates Submission of a Rolling NDA to the FDA for UGN-102
January 24, 2024
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Secures Exclusive License from medac GmbH to Develop a Next-Generation Novel Mitomycin-Based Formulation for Urothelial Cancers
January 17, 2024
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Pharma to Participate in the B. Riley Healthcare Conference
January 11, 2024
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 08, 2023
From
UroGen Pharma Ltd.
Via
Business Wire
Two Months After Hamas Attacks, Gaza Conflict Intensifies As Ceasefire Efforts Falter
December 07, 2023
Via
Benzinga
UroGen Pharma Reports Third Quarter 2023 Financial Results
November 14, 2023
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen will Present Scientific Advances in Bladder Cancer at the Annual Meeting of the Society of Urologic Oncology
November 13, 2023
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Pharma to Report Third Quarter 2023 Financial Results on Tuesday, November 14, 2023
November 07, 2023
From
UroGen Pharma Ltd.
Via
Business Wire
Cathie Wood's ARK Israel Innovative Tech ETF Braces For Impact Amid Regional Warfare: 10 Stocks To Watch
October 09, 2023
Via
Benzinga
Topics
ETFs
Following Pre-NDA Meeting with the FDA, UroGen Announces Rolling NDA Submission for UGN-102 to Begin January 2024
October 03, 2023
From
UroGen Pharma Ltd.
Via
Business Wire
Eledon Pharmaceuticals Appoints Industry Veteran James Robinson to its Board of Directors
September 11, 2023
From
Eledon Pharmaceuticals, Inc.
Via
GlobeNewswire
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 08, 2023
From
UroGen Pharma Ltd.
Via
Business Wire
UroGen Pharma to Present at Upcoming Investor Conferences
August 31, 2023
From
UroGen Pharma Ltd.
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.